For NeoGenomics use only

Solid Tumor Oncology Requisition Form



	Email: Client.Services@NeoGenomics	s.com Order Online: Nec	Link.NeoGenomics.com	
The following supplemental documentation is attached: Pathology Report Insurance Information Clinical Notes Relevant Test Results Please complete and return by fax or email. Incomplete or missing data may result in delayed testing. Bold fields are required.				
CLIENT INFORMATION		PATIENT INFORMATION		
Account Number	Account Name	First Name / Middle Initial / I	ast Name	
Street Address		Date of Birth MM/DD/YYYY	Biological Sex M F Unknown	
City, State, Zip		Street Address	M F Unknown	
Phone#	Fax#	City, State, Zip		
Req Completed By	Date	Phone#	Mobile Home	
Ordering Physician	NPI#	Email	noone nome	
Treating Oncologist/Physician	NPI#	Medical Record #		
BILLING INFORMATION ** Please include face sheet and insurance card **				
Bill Type Medicare Insurance/Medicaid Patient Self Pay Hospital/Institution If billing charges to other Hospital/Facility:				
Patient Status at Time of Specimen Collection Office (non-hospital) Hospital Outpatient Hospital Inpatient, Date of Discharge / / Primary Insurance Plan Policy Holder				
Subscriber ID	Group#		Prior Authorization #	
Policy Holder DOB / / Patient	t Relationship to Policy Holder Self S	pouse Child Other:		
SUPPLIES THE SUPPLIES AND DELEVAN	T CLUSCOL LUCTORY			
CURRENT DIAGNOSIS AND RELEVAN Date of Original Diagnosis / /	Diagnosis		Primary ICD-10 Codes (C & D codes only)	
		other:	Timaly leb 20 dates (e a b codes only)	
Type Breast Colorectal Gastri	c Melanoma Lung Ovarian C IIIB IV Unknown			
Disease Status Initial Diagnosis	Progression R/R (Relapsed/Refracto			
TEGT OF LEGISON				
TEST SELECTION Pan-Solid Tumor CGP Tests		Tissue		
TEST SELECTION Pan-Solid Tumor CGP Tests	Neo PanTracer Tissue (DNA/RNA NGS – 517 Genes with MSI and TMB)		Tissue + HRD (DNA/RNA NGS – MSI, TMB and HRD [Ovarian only])	
	517 Genes with MSI and TMB) Add-On Tiss	Neo PanTracer	MSI, TMB and HRD [Ovarian only]) IHC tests will report separately	
	517 Genes with MSI and TMB) Add-On Tiss PD-L1 22C3 FOLR1 (Ovarian) H	Neo PanTracer 517 Genes with ue IHC with any PanTracer test ER2 Breast HER2 (Gastric S	MSI, TMB and HRD [Ovarian only]) IHC tests will report separately coring) Claudin18 (Gastric) c-MET CDx (NSCI	_C)
Pan-Solid Tumor CGP Tests	517 Genes with MSI and TMB) Add-On Tiss PD-L1 22C3 FOLR1 (Ovarian) H CancerTYPE ID for unknown/uncertain tum	Neo PanTracer 517 Genes with ue IHC with any PanTracer test ER2 Breast HER2 (Gastric So or type with Pathologist Directed	MSI, TMB and HRD [Ovarian only]) IHC tests will report separately coring) Claudin18 (Gastric) c-MET CDx (NSCI NGS with PD-L1 22C3 IHC add-on	_C)
	517 Genes with MSI and TMB) Add-On Tiss PD-L1 22C3 FOLR1 (Ovarian) H CancerTYPE ID for unknown/uncertain tum Early-Stage NSCLC (EGFR, ALK, Sarcon	Neo PanTracer 517 Genes with ue IHC with any PanTracer test ER2 Breast HER2 (Gastric S	MSI, TMB and HRD [Ovarian only]) IHC tests will report separately coring) Claudin18 (Gastric) c-MET CDx (NSCI NGS with PD-L1 22C3 IHC add-on NeoTYPE DNA & RNA - Brain (DNA/RNA NGS - 83 genes with MSI and TMB)	_C)
Pan-Solid Tumor CGP Tests	517 Genes with MSI and TMB) Add-On Tiss PD-L1 22C3 FOLR1 (Ovarian) H CancerTYPE ID for unknown/uncertain tum Early-Stage NSCLC (EGFR, ALK, Sarcon	Neo PanTracer 517 Genes with ue IHC with any PanTracer test – ER2 Breast HER2 (Gastric So or type with Pathologist Directed na Comprehensive NGS Fusion	MSI, TMB and HRD [Ovarian only]) IHC tests will report separately coring) Claudin18 (Gastric) c-MET CDx (NSCI NGS with PD-L1 22C3 IHC add-on NeoTYPE DNA & RNA - Brain (DNA/RNA NGS - 83 genes with MSI and TMB) Add-On: PD-L1 LDT IHC	_C)
Pan-Solid Tumor CGP Tests Disease-Specific Profiles	517 Genes with MSI and TMB) Add-On Tiss PD-L1 22C3 FOLR1 (Ovarian) H CancerTYPE ID for unknown/uncertain tum Early-Stage NSCLC (EGFR, ALK, Sarcon	Neo PanTracer 517 Genes with ue IHC with any PanTracer test – ER2 Breast HER2 (Gastric So or type with Pathologist Directed na Comprehensive NGS Fusion	MSI, TMB and HRD [Ovarian only]) IHC tests will report separately coring) Claudin18 (Gastric) c-MET CDx (NSCI NGS with PD-L1 22C3 IHC add-on NeoTYPE DNA & RNA - Brain (DNA/RNA NGS - 83 genes with MSI and TMB)	.c)
Pan-Solid Tumor CGP Tests Disease-Specific Profiles Other: TISSUE SPECIMEN LOCATION INFORM	517 Genes with MSI and TMB) Add-On Tiss PD-L1 22C3 FOLR1 (Ovarian) H CancerTYPE ID for unknown/uncertain tum Early-Stage NSCLC (EGFR, ALK, ROS1, PD-L1 22C3) Panel (Neo PanTracer 517 Genes with ue IHC with any PanTracer test – ER2 Breast HER2 (Gastric So or type with Pathologist Directed na Comprehensive NGS Fusion	MSI, TMB and HRD [Ovarian only]) IHC tests will report separately coring) Claudin18 (Gastric) c-MET CDx (NSCI NGS with PD-L1 22C3 IHC add-on NeoTYPE DNA & RNA - Brain (DNA/RNA NGS - 83 genes with MSI and TMB) Add-On: PD-L1 LDT IHC	.C)
Pan-Solid Tumor CGP Tests Disease-Specific Profiles Other:	517 Genes with MSI and TMB) Add-On Tiss PD-L1 22C3 FOLR1 (Ovarian) H CancerTYPE ID for unknown/uncertain tum Early-Stage NSCLC (EGFR, ALK, ROS1, PD-L1 22C3) Panel (Neo PanTracer 517 Genes with ue IHC with any PanTracer test – ER2 Breast HER2 (Gastric So or type with Pathologist Directed na Comprehensive NGS Fusion	MSI, TMB and HRD [Ovarian only]) IHC tests will report separately coring) Claudin18 (Gastric) c-MET CDx (NSCI NGS with PD-L1 22C3 IHC add-on NeoTYPE DNA & RNA - Brain (DNA/RNA NGS - 83 genes with MSI and TMB) Add-On: PD-L1 LDT IHC	LC)
Pan-Solid Tumor CGP Tests Disease-Specific Profiles Other: TISSUE SPECIMEN LOCATION INFORM	517 Genes with MSI and TMB) Add-On Tiss PD-L1 22C3 FOLR1 (Ovarian) H CancerTYPE ID for unknown/uncertain tum Early-Stage NSCLC (EGFR, ALK, ROS1, PD-L1 22C3) Panel (Neo PanTracer 517 Genes with ue IHC with any PanTracer test – ER2 Breast HER2 (Gastric So or type with Pathologist Directed na Comprehensive NGS Fusion	MSI, TMB and HRD [Ovarian only]) IHC tests will report separately coring) Claudin18 (Gastric) c-MET CDx (NSCI NGS with PD-L1 22C3 IHC add-on NeoTYPE DNA & RNA - Brain (DNA/RNA NGS - 83 genes with MSI and TMB) Add-On: PD-L1 LDT IHC	C)
Pan-Solid Tumor CGP Tests Disease-Specific Profiles Other: TISSUE SPECIMEN LOCATION INFORM Pathology Lab Name	517 Genes with MSI and TMB) Add-On Tiss PD-L1 22C3 FOLR1 (Ovarian) H CancerTYPE ID for unknown/uncertain tum Early-Stage NSCLC (EGFR, ALK, ROS1, PD-L1 22C3) Panel (Neo PanTracer 517 Genes with ue IHC with any PanTracer test – ER2 Breast HER2 (Gastric So or type with Pathologist Directed na Comprehensive NGS Fusion	MSI, TMB and HRD [Ovarian only]) IHC tests will report separately coring) Claudin18 (Gastric) c-MET CDx (NSCI NGS with PD-L1 22C3 IHC add-on NeoTYPE DNA & RNA - Brain (DNA/RNA NGS - 83 genes with MSI and TMB) Add-On: PD-L1 LDT IHC	.c)
Pan-Solid Tumor CGP Tests Disease-Specific Profiles Other: TISSUE SPECIMEN LOCATION INFORM Pathology Lab Name City, State, Zip Phone#	517 Genes with MSI and TMB) Add-On Tiss PD-L1 22C3 FOLR1 (Ovarian) H CancerTYPE ID for unknown/uncertain tum Early-Stage NSCLC (EGFR, ALK, ROS1, PD-L1 22C3) Panel (Neo PanTracer 517 Genes with ue IHC with any PanTracer test – ER2 Breast HER2 (Gastric So or type with Pathologist Directed na Comprehensive NGS Fusion RNA NGS - 97 genes)	MSI, TMB and HRD [Ovarian only]) IHC tests will report separately coring) Claudin18 (Gastric) c-MET CDx (NSCI NGS with PD-L1 22C3 IHC add-on NeoTYPE DNA & RNA - Brain (DNA/RNA NGS - 83 genes with MSI and TMB) Add-On: PD-L1 LDT IHC Add-On: MGMT Promoter Methylation Analysis	LC)
Pan-Solid Tumor CGP Tests Disease-Specific Profiles Other: TISSUE SPECIMEN LOCATION INFORM Pathology Lab Name City, State, Zip Phone#	Add-On Tiss PD-L1 22C3 FOLR1 (Ovarian) H CancerTYPE ID for unknown/uncertain tum Early-Stage NSCLC (EGFR, ALK, ROS1, PD-L1 22C3) Panel (Neo PanTracer 517 Genes with ue IHC with any PanTracer test – ER2 Breast HER2 (Gastric So or type with Pathologist Directed na Comprehensive NGS Fusion RNA NGS - 97 genes)	MSI, TMB and HRD [Ovarian only]) IHC tests will report separately coring) Claudin18 (Gastric) c-MET CDx (NSCI NGS with PD-L1 22C3 IHC add-on NeoTYPE DNA & RNA - Brain (DNA/RNA NGS - 83 genes with MSI and TMB) Add-On: PD-L1 LDT IHC Add-On: MGMT Promoter Methylation Analysis	_C)
Pan-Solid Tumor CGP Tests Disease-Specific Profiles Other: TISSUE SPECIMEN LOCATION INFORM Pathology Lab Name City, State, Zip Phone# For molecular/NGS testing, if NeoGenomics ret Instructions	Add-On Tiss PD-L1 22C3 FOLR1 (Ovarian) H CancerTYPE ID for unknown/uncertain tum Early-Stage NSCLC (EGFR, ALK, ROS1, PD-L1 22C3) Panel (Neo PanTracer 517 Genes with ue IHC with any PanTracer test – ER2 Breast HER2 (Gastric So or type with Pathologist Directed na Comprehensive NGS Fusion RNA NGS - 97 genes)	MSI, TMB and HRD [Ovarian only]) IHC tests will report separately coring) Claudin18 (Gastric) c-MET CDx (NSCI NGS with PD-L1 22C3 IHC add-on NeoTYPE DNA & RNA - Brain (DNA/RNA NGS - 83 genes with MSI and TMB) Add-On: PD-L1 LDT IHC Add-On: MGMT Promoter Methylation Analysis	LC)
Pan-Solid Tumor CGP Tests Disease-Specific Profiles Other: TISSUE SPECIMEN LOCATION INFORM Pathology Lab Name City, State, Zip Phone# For molecular/NGS testing, if NeoGenomics ret	Add-On Tiss PD-L1 22C3 FOLR1 (Ovarian) H CancerTYPE ID for unknown/uncertain tum Early-Stage NSCLC (EGFR, ALK, ROS1, PD-L1 22C3) MATION Fax# trieves multiple blocks, our pathologists will con	Neo PanTracer 517 Genes with ue IHC with any PanTracer test – ER2 Breast HER2 (Gastric So or type with Pathologist Directed na Comprehensive NGS Fusion RNA NGS - 97 genes)	MSI, TMB and HRD [Ovarian only]) IHC tests will report separately coring) Claudin18 (Gastric) c-MET CDx (NSCI NGS with PD-L1 22C3 IHC add-on NeoTYPE DNA & RNA - Brain (DNA/RNA NGS - 83 genes with MSI and TMB) Add-On: PD-L1 LDT IHC Add-On: MGMT Promoter Methylation Analysis	LC)
Disease-Specific Profiles Other: TISSUE SPECIMEN LOCATION INFORM Pathology Lab Name City, State, Zip Phone# For molecular/NGS testing, if NeoGenomics ret Instructions Physician is requesting a specific specimen Specimen ID:	Add-On Tiss PD-L1 22C3 FOLR1 (Ovarian) H CancerTYPE ID for unknown/uncertain tum Early-Stage NSCLC (EGFR, ALK, ROS1, PD-L1 22C3) MATION Fax# trieves multiple blocks, our pathologists will con	Neo PanTracer 517 Genes with ue IHC with any PanTracer test – ER2 Breast HER2 (Gastric So or type with Pathologist Directed na Comprehensive NGS Fusion RNA NGS - 97 genes)	MSI, TMB and HRD [Ovarian only]) IHC tests will report separately coring) Claudin18 (Gastric) c-MET CDx (NSCI NGS with PD-L1 22C3 IHC add-on NeoTYPE DNA & RNA - Brain (DNA/RNA NGS - 83 genes with MSI and TMB) Add-On: PD-L1 LDT IHC Add-On: MGMT Promoter Methylation Analysis	LC)
Pan-Solid Tumor CGP Tests Disease-Specific Profiles Other: TISSUE SPECIMEN LOCATION INFORM Pathology Lab Name City, State, Zip Phone# For molecular/NGS testing, if NeoGenomics ret Instructions Physician is requesting a specific specimen	Add-On Tiss PD-L1 22C3 FOLR1 (Ovarian) H CancerTYPE ID for unknown/uncertain tum Early-Stage NSCLC (EGFR, ALK, ROS1, PD-L1 22C3) MATION Fax# trieves multiple blocks, our pathologists will con	Neo PanTracer 517 Genes with ue IHC with any PanTracer test – ER2 Breast HER2 (Gastric So or type with Pathologist Directed na Comprehensive NGS Fusion RNA NGS - 97 genes)	MSI, TMB and HRD [Ovarian only]) IHC tests will report separately coring) Claudin18 (Gastric) c-MET CDx (NSCI NGS with PD-L1 22C3 IHC add-on NeoTYPE DNA & RNA - Brain (DNA/RNA NGS - 83 genes with MSI and TMB) Add-On: PD-L1 LDT IHC Add-On: MGMT Promoter Methylation Analysis	LC)

Full test menu at NeoGenomics.com

My signature certifies that (1) I am the patient's treating physician and am authorized under applicable law to order the tests on this test requisition, (2) each test ordered on this test requisition is medically necessary for the patient, (3) the results of each test will inform the patient's ongoing treatment plan, (4) I have explained to the patient the nature and purpose of each test to be performed pursuant to this test requisition, and the patient has had the opportunity to ask questions regarding each test and the collection, use, and disclosure of his/her samples and data, (5) I have obtained informed consent from the patient.

Solid Tumor Oncology Requisition Form



Additional Billing Information Any organization referring specimens for testing services pursuant to this Requisition Form ("Client") expressly agrees to the following terms and conditions.

- **1. Binding Service Order.** This Requisition Form is a contractually binding order for the services ordered hereunder ("Services") and Client agrees that it is financially responsible for all tests billable to Client hereunder.
- 2. Third-Party Billing by NeoGenomics and Right to Bill Client. Client agrees to accurately indicate on the front of the Requisition Form that either Client should be billed (e.g., Client receives reimbursement pursuant to a non-fee-for-service basis, including, but not limited to, a capitated, diagnostic related group ("DRG"), per diem, all-inclusive, or other such bundled or consolidated billing arrangement) or NeoGenomics should bill the applicable federal, state, or commercial health insurer or other third-party payer (collectively, "Payers") for all Services ordered pursuant to this Requisition Form. For all such Services billable to Payers, Client agrees to provide all billing information necessary for NeoGenomics to bill such payer. In the event that NeoGenomics: (i) does not receive the billing information required for it to bill any Payers within ten (10) days of the date that any Services are reported by NeoGenomics; (ii) the Services were performed for patients who have no Payer coverage arrangements; or (iii) the Payer identified by Client denies financial responsibility for the Services and indicates that Client is financially responsible, NeoGenomics shall have the right to bill such Services to Client.

Specimen Requirements & Usage NeoGenomics makes every effort to preserve and not exhaust tissue, but in small and thin specimens, there is a possibility of exhausting the specimen in order to ensure adequate material and reliable results.

For molecular/NGS tissue testing, the following is requested: A single block for large resections where tumor is abundant, or up to 4 blocks from procedures with smaller specimens (e.g. Core biopsy, cell block). Only blocks from the same procedure and same tumor should be submitted together. Please call the Client Services team with any questions regarding specimen information.

All other tests: Refrigerate specimen if not shipping immediately and use cool pack during transport. A block is preferred for testing; please see individual test webpages for specimen requirements.

Please call our Client Services team with questions regarding specimen requirements or shipping instructions at 866.776.5907, option 3. Please refer to **NeoGenomics.com** for specific details on each specimen.

PanTracer Tissue and NeoTYPE DNA & RNA - Brain Profiles: If the sample is insufficient to produce either DNA or RNA results, the available results will be reported and alternate CPT Codes may apply.

CancerTYPE ID* with reflex to pathologist directed NGS option, with PD-L1 22C3 added if not already included in NGS test. NGS Cancer Profile determined by the CancerTYPE ID result. CancerTYPE ID will be performed, reported, and billed separately by Biotheranostics, Inc. For comprehensive details about CancerTYPE ID including test description, intended use, and limitations, visit **CancerTypeID.com**.

Test Descriptions For our complete test menu, turnaround times, specimen requirements, and more, please visit NeoGenomics.com/Test-Menu